Characterising post-COVID syndrome more than 6 months after acute infection in adults; prospective longitudinal cohort study, England

Zahin Amin-Chowdhury, BSc¹, Ross J Harris, PhD², Felicity Aiano, MSc¹, Maria Zavala, MSc¹, Marta Bertran, MSc¹, Ray Borrow, PhD³, Ezra Linley³, PhD, Shazaad Ahmad FRCPATH⁴, Ben Parker^{5,6}, Alex Horsley^{5,7}, Bassam Hallis, PhD⁸, Jessica Flood, PhD¹, Kevin E Brown FRCPATH⁹, Gayatri Amirthalingam, MFPH¹, Mary E Ramsay, FFPH¹, Nick Andrews, PhD^{1,3}, Shamez N Ladhani, MRCPCH^{1,10}

¹ Immunisation and Countermeasures Division, Public Health England, Colindale, London NW9 5EQ, UK

² Statistics, Modelling, and Economics Department, Public Health England, Colindale, London NW9 5EQ, UK

³ Sero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL

⁴ Department of Virology, Manchester Medical Microbiology Partnership, Manchester Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.

⁵ The NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK

⁶ Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK

⁷ Division of Infection, Immunity and Respiratory Medicine, University of Manchester,
Manchester, UK

⁸ Immunoassay Lab, National Infection Service, Porton Down SP4 0JG

⁹ Virus Reference Department, Reference Microbiology, National Infection Service, Public
Health England Colindale. 61 Colindale Avenue, London NW9 5EQ

¹⁰ Paediatric Infectious Diseases Research Group (PIDRG), St. George's University of
London, Cranmer Terrace, London SW17 0RE, UK.

Key points (40-word summary):

Compared to controls, we identified three clusters of symptoms affecting the sensory, neurological and cardiorespiratory systems that were more prevalent among cases. Notably, gastrointestinal and dermatological symptoms and symptoms related to mental health were as prevalent among cases as controls.

Word count: 3,585

Key words: long COVID, prospective cohort, control group

Short title: Long COVID in adults

Corresponding Author: Dr Shamez Ladhani, Immunisation and Countermeasures Division,
Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK. Email:
shamez.ladhani@phe.gov.uk

Alternate Corresponding Author: Zahin Amin-Chowdhury, Immunisation and
Countermeasures Division, Public Health England, 61 Colindale Avenue, London NW9 5EQ,
UK. Email: zahin.amin@phe.gov.uk

ICMJE criteria for authorship was met by all authors.

Abstract

Background

Most individuals with COVID-19 will recover without sequelae, but some will develop long-term multi-system impairments. The definition, duration, prevalence and symptoms associated with long COVID, however, have not been established.

Methods

Public Health England (PHE) initiated longitudinal surveillance of clinical and non-clinical healthcare workers for monthly blood sampling for SARS-CoV-2 antibodies in March 2020. Eight months after enrolment, participants completed an online questionnaire including 72 symptoms in the preceding month. Symptomatic mild-to-moderate cases with confirmed COVID-19 were compared with asymptomatic, seronegative controls. Multivariable logistic regression was used to identify independent symptoms associated with long COVID.

Results

All 2,147 participants were contacted and 1,671 (77.8%) completed the questionnaire, including 140 (8.4%) cases and 1,160 controls. At a median of 7.5 (IQR 7.1-7.8) months after infection, 20 cases (14.3%) had ongoing (4/140, 2.9%) or episodic (16/140, 11.4%) symptoms. We identified three clusters of symptoms associated with long COVID, those affecting the sensory (ageusia, anosmia, loss of appetite and blurred vision), neurological (forgetfulness, short-term memory loss and confusion/brain fog) and cardiorespiratory (chest tightness/pain, unusual fatigue, breathlessness after minimal exertion/at rest, palpitations) systems. The sensory cluster had the highest association with being a case (aOR 5.25, 95% CI 3.45-8.01). Dermatological, gynaecological, gastrointestinal or mental health symptoms were not significantly different between cases and controls.

Conclusions

Most persistent symptoms reported following mild COVID-19 were equally common in cases and controls. While all three clusters identified had a strong association with previous COVID-19 infection, the sensory cluster had the highest specificity and strength of association.

Introduction

The clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the virus responsible for coronavirus disease 19 (COVID-19) – range from asymptomatic infection to severe disease leading to multi-organ failure and death.^{1, 2} While for many survivors, the infection is mild and short-lived, with emerging evidence, it is now recognised that an as-yet undefined proportion will go on to develop persistent symptoms after recovering from their infection.³ Various terms have been used to describe the condition, including ‘post-acute COVID-19’, ‘post-COVID-19 syndrome’ and ‘long COVID’.^{4, 5} In the UK, NICE–SIGN–RCGP have developed guidelines to support patients with long COVID, but the definition for this condition is very non-specific, and includes any individual with signs and symptoms that develop during or after an infection consistent with COVID-19, continuing for more than 12 weeks and are not explained by an alternative diagnosis.⁶

The reported symptoms in individuals recovering from COVID-19 are varied and may manifest as episodic, cyclical or persistent. Symptoms affecting every organ system have been described, particularly affecting the cardiovascular, respiratory and neuromuscular system, as well as non-specific symptoms such as excessive fatigue, body aches and “brain fog”.^{7, 8} Chronic fatigue has also been widely reported in some patients recovering from COVID-19, which is not surprising given that this syndrome can occur after any infection.^{7, 8} Currently, our understanding of long COVID-19 comes from information provided by patients with COVID-19, usually those who were hospitalised and, therefore, experienced more severe disease.^{9, 10} Additionally, published studies have been limited self-selected cohorts of patients and lack of appropriate control groups to objectively assess the relative frequency of reported symptoms, which have led to surprisingly high estimates of long COVID prevalence estimates, with a pooled estimate of 80% in one systematic review. Some of the >170 symptoms reportedly caused by COVID-19 have low biological plausibility but cannot be excluded without knowledge of their frequency in the general population.^{5, 11}

At the start of the pandemic, Public Health England (PHE) initiated active prospective surveillance of more than 2,000 clinical and non-clinical healthcare workers to collect monthly blood samples for SARS-CoV-2 antibody testing.¹² Around 12% developed COVID-19, mainly during March/April 2020. In order to better understand the characteristics of long COVID in healthy adults with mild-to moderate COVID-19, we asked all participants to complete an online questionnaire about their physical and mental state in November 2020. Knowledge of their SARS-CoV-2 RT-PCR and antibody status allowed us to accurately identify laboratory-confirmed symptomatic COVID-19 cases along with a large control group of asymptomatic adults who remained SARS-CoV-2 antibody negative throughout the surveillance period. Our objective was to estimate the prevalence of persistent symptoms in working-age adults with confirmed COVID-19. We also compared reported long COVID symptoms identified through a literature review and mental health state of individuals with confirmed COVID-19 more than 6 months after their infection with the asymptomatic, SARS-CoV-2 antibody negative controls.

Methods

Study design and participants

In March 2020, PHE initiated a prospective cohort study (ESCAPE) of PHE and National Health Service (NHS) healthcare workers to collect monthly blood samples for SARS-CoV-2 antibodies at multiple sites in England (PHE London, PHE Porton Down, PHE Manchester, NHS Manchester Royal Infirmary and NHS Wythenshawe Hospital).¹² Participants included office-based workers, laboratory workers, as well as clinical patient-facing and non-patient facing healthcare workers, most of whom working on-site throughout national lockdown. Participants were provided with information about the study and provided written informed consent prior to enrolment. A short online questionnaire requesting information about any illness, symptoms and SARS-CoV-2 testing since the previous blood sampling visit was

completed on-site by the participant at each blood sampling visit. If participants missed a visit, they could still continue to take part at the next visit.¹³

Questionnaire design

To assess any long-term effects of COVID-19, participants were invited to complete a detailed online questionnaire in November 2020. The questionnaire was developed based on all possible symptoms associated with long COVID that were reported online or in the scientific literature.^{14, 15} The questionnaire was piloted among adults with and without COVID-19 and revised according to feedback received. The final questionnaire (**Supplement 1**) included questions on demographics, COVID-19 symptoms, PCR testing, chronic health conditions as well as whether they or not they had experienced any of 72 symptoms in the month prior to questionnaire completion. Symptoms were sub-grouped into (1) neurological, (2) dermatological, (3) sensory, (4) respiratory, (5) gastrointestinal, (6) cardiovascular, (7) mental health, and (8) other. The questionnaire was disseminated to ESCAPE participants electronically using the Snap Professional 11 platform on 03 November 2020. Participants received regular email reminders to complete the questionnaire until the survey closed on 12 February 2021.

Laboratory methods

The laboratory methods for SARS-CoV-2 antibody testing are described elsewhere.¹² In brief, blood samples were tested using five different assays for Nucleoprotein (Roche N and Abbott) and for Spike (EUROIMMUN, Roche S, and an in-house assay named RBD) antibodies. A participant was seropositive if positive for Nucleoprotein or Spike antibodies in any assay. Indeterminate results and insufficient samples were excluded.

Definitions

A case was defined as any participant with COVID-19 symptoms and laboratory-confirmed positive SARS-CoV-2 antibodies with an interval of at least 6 months from their first positive SARS-CoV-2 RT-PCR test or, if not tested, the onset of their COVID-19 symptoms until

questionnaire completion. The uninfected control group comprised SARS-CoV-2 antibody negative participants who remained asymptomatic until questionnaire completion.

Participants who became SARS-CoV-2 RT-PCR or antibody positive within 6 months of questionnaire completion were not included in the analysis, as were those with COVID-19 symptoms who were SARS-CoV-2 antibody negative >30 days after their illness and those who developed COVID-19 symptoms after their last negative antibody test.

Data management and statistical analyses

Data were managed using Microsoft Access (Microsoft Corporation, Redmond, Washington) and analysed using Stata 15.1 (StataCorp LLC, College Station, Texas). Participant characteristics were described as counts and proportions. Non-normally distributed continuous variables are presented as medians with interquartile range. Categorical data are presented as a frequency (percentage) and compared using χ^2 , Fisher's exact or Kruskal-Wallis tests as appropriate, unless otherwise stated.

Logistic regression models were fitted for symptoms identified as statistically significant ($p < 0.05$) in the univariable χ^2 or Fisher's exact test, as appropriate and adjusted for age group, sex, comorbidity status, ethnicity and workplace role. Because of multiple comparisons, a p value of ≤ 0.001 was considered statistically significant. Symptoms with less than 5% reported in cases and controls were also excluded due to being extremely rare. Potential interactions between covariates were assessed using likelihood ratio tests. The controls were compared with antibody positive participants which were excluded to assess for significant difference. The results are reported as odd ratios (OR) and adjusted odds ratios (aOR) with 95% confidence intervals (CI). Symptoms within organ systems of both clinical and statistical significance were regrouped and fitted into logistic regression models adjusting for covariates described above.¹⁶

Results

Participant characteristics

All 2,147 ESCAPE participants were contacted by email and 1,671 (77.8%) completed the online questionnaire. Asymptomatic, antibody positive participants (n=73), those who developed COVID-19 within 6 months of completing the questionnaire (n=172) and those reporting COVID-19 symptoms or a positive RT-PCR result who remained SARS-CoV-2 antibody negative more than 30 days after their illness (n=126) were excluded (**Figure 1**). There were, therefore, 140 confirmed cases (10.8%), including 37 with PCR-confirmed COVID-19 and 103 with COVID-19 symptoms who had not been tested by RT-PCR. The median interval between illness and questionnaire completion in cases was 7.5 months (IQR 7.1-7.8). The control group comprised of 1,160 (89.2%) participants who remained asymptomatic and antibody negative throughout the surveillance period.

Participant characteristics are described in **Table 1**. The median age of cases was 41 (IQR 31-52) years, which was similar to the control group (42 [33-53]; p=0.12), as was the proportion who were female and those with underlying comorbidities. Workplace setting varied between cases and controls, with patient-facing hospital staff comprising a higher proportion of cases than controls (51.7% vs 23.0%). None of the cases were hospitalised for COVID-19.

Persisting symptoms

Most participants reported that they recovered without persisting symptoms, but 14.7% (20/140) had ongoing (4/140, 2.9%) or episodic (16/140, 11.4%) symptoms after COVID-19 (**Table 1**). The four participants with ongoing symptoms were female, none had underlying comorbidities and all reported unusual fatigue and breathlessness after minimal exertion in

the month prior to questionnaire completion, with three also reporting confusion, forgetfulness, muscle aches and anxiety. Of the 16 cases with episodic symptoms, 12 (75.0%) were female and 2/16 (12.5%) had at least one or more comorbidities. All 12 reported experiencing stress in the previous month, and more than three-quarters (75-94%) reported problems sleeping through the night, mood swings, forgetfulness, unusual fatigue, muscle aches or confusion/brain fog.

Cases versus controls

In the univariable analysis, 72 symptoms were compared in cases and controls (**Table 2**). The controls did not present with symptoms significantly different to antibody positive participants which were excluded from the analyses. Neurological symptoms of statistical significance included problems sleeping through the night (60.7% vs 51.5%), forgetfulness (35.0% vs 19.0%), confusion/brain fog/trouble focussing attention (20.7% vs 14.7%), trouble trying to form words (15.7% vs 9.2%), short-term memory loss (20.7% vs 5.6%) and, less frequently, difficulty swallowing (6.4% vs 2.4%), twitching of fingers and toes (5.7% vs 2.4%) and trembling (5.7% vs 1.7%). Respiratory symptoms of interest included unusual fatigue/tiredness after exertion (39.3% vs 17.5%), breathlessness after minimal exertion (25.7% vs 10.2%), chest tightness/pain (18.6% vs 8.2%), fits of coughing (13.6% vs 6.5%) and breathlessness at rest (9.3% vs 2.8%). Sensory symptoms included anosmia (18.6% vs 0.8%), ageusia (17.1% vs 0.6%), loss of appetite (14.3% vs 5.8%) and blurred vision (13.6% vs 6.9%). Palpitations was the only cardiovascular symptom of statistical significance (21.4% vs 11.5%). There were no significant symptoms within dermatological, gynaecological, gastrointestinal or mental health sub-groups. Rare symptoms (prevalence <5% in cases) of statistical significance including slurred speech, hallucinations and collapse were excluded from further analyses (**Table 2**).

Other noteworthy associations, in the logistic regression model, include that unusual fatigue and problems sleeping through the night were independently associated with being female compared to male (aOR 2.22; 95%CI 1.55-3.17 and aOR 1.97; 95%CI 1.53-2.54,

respectively) and having underlying comorbidities compared to having no comorbidity (aOR 1.98; 95%CI 1.34-2.93 and aOR 2.06; 95%CI 1.43-2.97, respectively), while forgetfulness (aOR 2.10; 95%CI 1.50-2.95) and palpitations (aOR 2.23; 95%CI 1.44-3.44) were only associated with being female. Additionally, breathlessness at rest (aOR 3.16; 95%CI 1.57-6.38), fits of coughing (aOR 2.93; 95%CI 1.78-4.82), chest tightness (aOR 2.88; 95%CI 1.79-4.63), breathlessness after minimal exertion (aOR 3.05; 95%CI 1.99-4.67), trembling (aOR 4.50; 95%CI 1.97-19.27), coughing when lying down (aOR 2.92; 95%CI 1.67-5.08); confusion (aOR 2.10; 95%CI 1.38-3.18) were associated with having at least one comorbidity.

After considering strength of association, prevalence in cases and control group and effect size, we determined symptoms that were associated with long COVID to be related to three clusters (**Table 3**). Sensory symptoms in order of effect size included loss of taste (aOR 39.69; 95%CI 15.50-101.61), loss of smell (aOR 33.88; 95%CI 14.45-79.45), loss of appetite and blurred vision. Neurological symptoms included forgetfulness, short-term memory loss (aOR 5.66; 95%CI 3.31-9.67) and confusion/brain fog. Cardiorespiratory symptoms included chest tightness/pain, unusual fatigue, breathlessness after minimal exertion (aOR 3.52; 95%CI 2.20-5.62), breathlessness at rest (aOR 3.51; 95%CI 1.68-7.32) and palpitations. The remaining symptoms that were no longer significant in the logistic regression model (at the $p \leq 0.001$ level) included trouble trying to form words, coughing when lying down, difficulty swallowing, twitching of fingers and toes, trembling, problems sleeping through the night, fits of coughing and metallic taste.

The adjusted odds ratios of the three identified clusters of symptoms within the sensory, neurological and cardiorespiratory systems are presented in **Table 4**. Two-thirds (67%) of cases had at least one or more symptoms of the three clusters (versus 44% controls) while one-fifth (20%) reported to having at least one symptom from all three clusters (versus 5% controls) (**Figure 2**). The sensory cluster had the highest association with being a case (aOR 5.25, 95% CI 3.45-8.01).

Discussion

Summary of findings

We followed-up a unique prospective cohort of clinical and non-clinical healthcare professionals who were regularly assessed for COVID-19 since the start of the pandemic. We identified 140 symptomatic cases with mild-to-moderate COVID-19, of whom 3% reported persistent symptoms and a further 11% reported episodic symptoms at a median of 7.5 months after infection. In the month prior to questionnaire completion, cases reported a higher frequency of symptoms affecting the senses, neurological and cardiorespiratory systems than 1,160 asymptomatic, seronegative controls. While cardiorespiratory symptoms including unusual fatigue, breathlessness at rest/after minimal exertion, chest tightness/pain and palpitations were most commonly reported by around half of cases, sensory symptoms had the strongest association, reported by 5 times as many cases as controls. Anosmia (19%) and ageusia (17%) in particular were each >30 times more likely to be reported among cases than controls. Importantly, we found high rates of mental health symptoms which were equally common among cases and controls, highlighting the global negative impact of the current pandemic on then mental health on healthcare workers.

Comparison with literature

There is currently no accepted case definition for symptoms or duration of long COVID.^{7, 17} Consequently, it is difficult to estimate the prevalence or characteristics of this new condition. Most of the early data on persistent symptoms emerged from follow-up of hospitalised adults with COVID-19, who had more severe illness and, consequently, reported a higher prevalence of ongoing symptoms. One Italian study of 143 patients, for example, who were predominantly male (63%) and with a median age of 57, found 87% of patients with COVID-19 had at least one residual symptom 36 days after hospital discharge,¹⁵ while a Canadian study of 78 patients, with similar sex ratio, mean age of 62 and comorbidity prevalence of

41%, reported >75% of patients experienced adverse outcomes three months after onset of symptoms.¹⁸ In both studies, worsened quality of life and dyspnoea were the most frequently reported adverse outcomes, reported by 40-50% of patients. Fatigue was also common (50%), followed by joint pain (27%) and cough (23%) Notably, persistent symptoms were similar in those with and without pre-existing comorbidities.¹⁸ Preliminary findings from a large cohort of hospitalised patients found ongoing symptoms reported by 93% of patients, with dyspnea (77%) and fatigue (56%) being most commonly reported at a median of 7 months after illness. Another UK study also found a very high proportion of patients (84%) with at least one residual symptom at follow-up after hospital discharge; this study found that females were significantly more likely to report residual symptoms than males, including anxiety, fatigue and myalgia.¹⁹ Taken together, these studies of hospitalised patients with COVID-19 are likely to identify high rates of persistent symptoms because of the older age, higher comorbidity prevalence and more severe disease of cases.²⁰

Data on sequelae in adults with mild-to-moderate COVID-19 are more limited. In the UK, the app-based COVID Symptom Study known as ZOE found that 13.3% of COVID-19 cases had persistent symptoms lasting >28 days, reducing to 4.5% after 8 weeks and 2.3% after 12 weeks.¹⁴ Increasing age, female sex, hospital attendance and asthma were independently associated with symptoms lasting beyond 28 days.¹⁴ By comparison, one-fifth of SARS-CoV-2 positive participants in the COVID Infection Survey (CIS) conducted by the UK Office for National Statistics (ONS) reported symptoms lasting for longer than 5 weeks and one-tenth exhibiting symptoms for more than 12 weeks.²¹

A major limitation with all such studies, as highlighted by our study, is the lack of a control group to allow attribution of specific symptoms to long COVID. This is exemplified by reported long COVID symptoms such as headache (44%) and hair loss (25%) which were among the top five prevailing symptoms in a systematic review of long COVID.⁵ In our cohort, hair loss was much rarer and not significantly different among cases and controls

(9.3% vs 7.4%, respectively), while headache was comparably common (46% cases vs. 47% controls).

One US study surveyed 357 COVID-19 cases (9 of whom were hospitalised, 2.5%), 5,497 SARS-CoV-2 negative controls, and 19,095 non-tested individuals and found that 42.3% of cases had at least one persisting symptom at 30 days compared to 13.3% and 8.6%, respectively, with 14.8% still have at least one symptom after 90 days.⁹ This survey found a higher risk of persistent symptoms in those who were initially more ill. The most significant persisting symptoms in those with COVID-19 were anosmia, ageusia, difficulty concentrating, dyspnoea, memory loss, confusion, chest pain, and pain with deep breaths.⁹

The findings are similar to our cohort. Interestingly, while 14% of those with COVID-19 in our cohort reported on-going symptoms after 6 months, most of their symptoms were non-specific and those with more typical persisting symptoms associated COVID-19 such as anosmia or ageusia did not consider them persistent symptoms associated with their initial COVID-19. It was only through specific questioning of individual symptoms that they reported the true range of their symptoms after COVID-19, highlighting the limitations of surveys that rely on self-reporting of symptoms.

The occurrence of anosmia and ageusia after viral infections is not new and occurs through inflammatory reaction of the nasal mucosa.²² With COVID-19, these features are now included in the case definition for acute COVID-19 and are most common among females. While most individuals recover within a few weeks, there are increasing reports of such symptoms persisting for many months after the acute illness,²³ as reported in our and the US cohort of individuals with mild-to-moderate COVID-19.⁹ Further follow-up studies are needed to assess the pathogenesis and long-term outcomes of sensory alterations associated with COVID-19.

As with the US survey, we also found a significantly higher prevalence of cardiorespiratory symptoms among cases than controls, although unusual fatigue/tiredness after minimal

exertion, breathlessness after minimal exertion and palpitations were also relatively frequently reported by controls (>10%). Not surprisingly, given the predilection of SARS-CoV-2 for the respiratory tract, hospitalised cases (a proxy for severe illness) and mild-to-moderate cases with predominantly respiratory symptoms are reported to be more likely to develop persistent respiratory symptoms at follow-up.⁹

The mechanisms underlying long COVID are largely unknown. It is likely that on-going inflammation, which may persist for several weeks after acute infection, contributes to persistent symptoms affecting specific organs such as the respiratory or cardiovascular systems.²⁴ For neurological complications, post-viral, immune-mediated disruption of the autonomic nervous system has been implicated.²⁵ It has been postulated that autoreactive T cells and SARS-CoV-2 antibodies that persist after viral clearance may cross-react with host self-antigens including those found in the central nervous system which could manifest as neurological symptoms.²⁶ Moreover, there is a precedent for long-term neuropsychiatric consequences after viral infection including post-viral fatigue which is well-described in the literature, including in previous pandemics such as the 1918 Spanish influenza where some patients were diagnosed with encephalitis lethargica post-infection, and, more recently, chronic myalgia, fatigue and disordered sleep following the 2003 SARS epidemic.^{27, 28}

Reassuringly, although we identified high rates of mental health symptoms among cases, the inclusion of a well-defined control group found almost identical rates among asymptomatic, seronegative individuals. These findings demonstrate the high toll of the pandemic on clinical and non-clinical healthcare workers that is not necessarily attributable to the infection itself. Some features, however, whilst not infrequent among controls, were significantly more common among cases, including confusion/brain fog/trouble focusing attention, short-term memory loss and forgetfulness. That they persist for more than six months after acute infection in our cohort is concerning and requires further study, including intervention to improve long-term outcomes. Similarly, as with other viral infections, some individuals with COVID-19 will develop chronic fatigue syndrome,⁸ and it is important that

these individuals are identified quickly to allow early interventions to improve long-term outcomes.

With respect to the other symptoms, the use of a case-control methodology provides some reassurance that gastrointestinal, rheumatological, dermatological, gynaecological and other non-specific symptoms reported in the literature are equally prevalent among cases and controls.

Strengths and limitations

The strength in this study lies in the early establishment of a prospective cohort of healthy adults with monthly follow-up including blood sampling and questionnaire completion as well as a high response rate of 78%. Our findings highlight the importance of including a representative cohort of cases to assess long-term outcomes of COVID-19 as well as appropriate controls to estimate the relative prevalence of self-reported symptoms to accurately define this new syndrome. There are, however, some limitations. The participants were clinical and non-clinical healthcare workers who may not be representative of the general population. Additionally, compared to controls, those with confirmed COVID-19 were more likely to be patient-facing, frontline clinical healthcare workers, who have also been working throughout the pandemic and, therefore, more likely to suffer from adverse physical, mental and emotional outcomes, including post-traumatic stress and burnout.²⁹ Another potential bias may result from participants already being aware of their SARS-CoV-2 RT-PCR and antibody status when completing the questionnaire. There may be also be some recall bias in that cases may have spent more time thinking about their symptoms than the asymptomatic control group. All these limitations, however, would increase the prevalence of symptoms – especially mental health symptoms – among cases compared to controls. The lack of a statistically significant difference for many of the symptoms, therefore, strongly suggest that these features are not associated with long COVID.

Conclusions

SARS-CoV-2 infection is associated with a broad spectrum of clinical disease, ranging from mild, transient respiratory illness to multi-organ failure requiring intensive care support. Recovery from infection will, therefore, vary according to severity of the initial illness and the organs affected. Assessment of an established cohort of healthy adults with mild-to-moderate COVID-19 and a well-defined group of asymptomatic, antibody negative controls identified a small group of patients with very specific persistent symptoms more than six months after infection. Our study adds to the evidence-base for the long-term effects of COVID-19 in adults with mild-to-moderate COVID-19 who contribute to the vast majority of 120+ million infections worldwide. This information is not only important for clinicians, patients and the public, but also for policy makers and healthcare providers who are investing heavily in long-term provisions for COVID-19 survivors. On-going surveillance will be important to monitor the physical and mental health of our cohort.

Ethics approval

This study was approved by PHE Research & Public Health Practice Ethics and Governance Group (R&D REGG Ref NR 0190).

Funding

This study was internally funded by Public Health England with additional support provided by the NIHR Manchester Clinical Research Facility. The study was also carried out at the NIHR Manchester Clinical Research Facility. AH and BP are supported by the NIHR Manchester Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NGS, the NIHR, of the Department of Health.

Patient and Public Involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research

Tables & Figures

Figure 1 Flowchart of participation in the study and selection of cases and uninfected control group

Table 1 Characteristics of cohort of cases and uninfected control group

Table 2 Univariable analysis of symptoms by infection status (case, control group)

Table 3 Multivariable logistic regression odds ratio (OR) and adjusted odds ratio (aOR) estimates of symptoms of interest

Table 4 Adjusted odds ratios (aOR) estimates using multivariable logistic models of symptoms of interest grouped by cluster

Figure 2 Venn diagrams representing the most common systems affected among cases compared to the control group

Figure 1 Flowchart of participation in the study and selection of cases and uninfected control group

Table 2 Characteristics of cohort of cases and uninfected control group

	Cases N (%) n=140	Control group N (%) n=1,160	Total N (%) n=1300
Age, median (IQR)	41 (31-52)	42 (33-52)	43 (33-53)
Age group			
20-29	29 (20.3%)	177 (15.2%)	206 (15.8%)
30-39	34 (23.8%)	282 (24.2%)	316 (24.2%)
40-49	39 (27.3%)	314 (27.0%)	353 (27.0%)
50-59	35 (24.5%)	284 (24.4%)	319 (24.4%)
60+	6 (4.2%)	107 (9.2%)	113 (8.6%)
Sex			
Male	41 (28.7%)	362 (31.1%)	403 (30.8%)
Female	102 (71.3%)	802 (68.9%)	904 (69.2%)
Ethnicity			
White	108 (76.1%)	994 (85.8%)	1102 (84.7%)
Black African/Caribbean	7 (4.9%)	26 (2.2%)	33 (2.5%)
Indian sub-continent	12 (8.5%)	75 (6.5%)	87 (6.7%)
Mixed	4 (2.8%)	13 (1.1%)	17 (1.3%)
Other	11 (7.7%)	51 (4.4%)	62 (4.8%)
Workplace setting			
Hospital with regular patient contact	74 (51.7%)	268 (23.0%)	342 (26.2%)
Hospital with occasional patient contact	10 (7.0%)	114 (9.8%)	124 (9.5%)
Hospital with no patient contact	13 (9.1%)	137 (11.8%)	150 (11.5%)
Office-based/PHE laboratory	33 (23.1%)	453 (38.9%)	486 (37.2%)
Working from home	6 (4.2%)	133 (11.4%)	139 (10.6%)
Other	7 (4.9%)	59 (5.1%)	66 (5.0%)
Symptom group			
Ongoing	5 (3.5%)	-	5 (0.4%)
Episodic	16 (11.2%)	-	16 (1.2%)
Well	122 (85.3%)	1164 (100.0%)	1286 (98.4%)
Has one or more comorbidities	26 (18.4%)	133 (11.6%)	159 (12.4%)
Hospitalised for COVID-19	0 (0.0%)	-	0 (0.0%)

Table 2 Univariable analysis of symptoms by infection status (case, control group)

Symptom group / symptom	Total N (%) N=1,300	Case N (%) N=140	Control group N (%) N=1,160	P-value
Neurological				
Problems with sleeping through the night	682	85 (60.7%)	597 (51.5%)	0.038
Forgetfulness	269	49 (35.0%)	220 (19.0%)	<0.001
Confusion/brain fog/trouble focusing attention	209	39 (27.9%)	170 (14.7%)	<0.001
Tingling/numbness/needle pains in arms/legs	168	25 (17.9%)	143 (12.3%)	0.065
Seizures	0	0 (0.0%)	0 (0.0%)	-
Collapse	4	2 (1.4%)	2 (0.2%)	0.011
Trembling	28	8 (5.7%)	20 (1.7%)	0.002
Twitching of fingers and toes	36	8 (5.7%)	28 (2.4%)	0.025
Short-term memory loss	94	29 (20.7%)	65 (5.6%)	<0.001
Trouble trying to form words	129	22 (15.7%)	107 (9.2%)	0.015
Headache	606	65 (46.4%)	541 (46.6%)	0.963
Hallucinations	4	3 (2.1%)	1 (0.1%)	<0.001
Dizziness	169	25 (17.9%)	144 (12.4%)	0.070
Difficulty swallowing	37	9 (6.4%)	28 (2.4%)	0.007
Other (neurological)	46	19 (13.6%)	27 (2.3%)	<0.001
Dermatological				
Dry/scaly skin	355	38 (27.1%)	317 (27.3%)	0.963
Itchy skin	343	38 (27.1%)	305 (26.3%)	0.829
Random bruising	102	13 (9.3%)	89 (7.7%)	0.502
Rashes	89	7 (5.0%)	82 (7.1%)	0.36
Hives	41	6 (4.3%)	35 (3.0%)	0.417
Other (dermatological)	22	2 (1.4%)	20 (1.7%)	0.798
Sensory				
Loss of smell	35	26 (18.6%)	9 (0.8%)	<0.001
Loss of appetite	87	20 (14.3%)	67 (5.8%)	<0.001
Loss of taste	31	24 (17.1%)	7 (0.6%)	<0.001
ringing/stroke buzzing in the ears	165	24 (17.1%)	141 (12.2%)	0.094
Blurred vision	99	19 (13.6%)	80 (6.9%)	0.005
Metallic taste in the mouth	64	14 (10.0%)	50 (4.3%)	0.003
Earache	108	14 (10.0%)	94 (8.1%)	0.442
Sensitivity to light	124	13 (9.3%)	111 (9.6%)	0.914
Flashing light in the eyes	85	12 (8.6%)	73 (6.3%)	0.303
Pressure behind the eyes	120	12 (8.6%)	108 (9.3%)	0.775
Slurred speech	12	6 (4.3%)	6 (0.5%)	<0.001
Other (sensory)	8	4 (2.9%)	4 (0.3%)	<0.001
Respiratory				
Breathlessness after minimal exertion	154	36 (25.7%)	118 (10.2%)	<0.001
Sore throat	296	34 (24.3%)	262 (22.6%)	0.651
Chest tightness/pain	121	26 (18.6%)	95 (8.2%)	<0.001
Fits of coughing	94	19 (13.6%)	75 (6.5%)	0.002

Coughing when lying down	80	14 (10.0%)	66 (5.7%)	0.045
Breathlessness at rest	46	13 (9.3%)	33 (2.8%)	<0.001
Asthmatic exacerbation	51	8 (5.7%)	43 (3.7%)	0.248
Having to sleep sitting upright	21	4 (2.9%)	17 (1.5%)	0.217
Other (respiratory)	12	3 (2.1%)	9 (0.8%)	0.110
Gastrointestinal				
Bloating	331	38 (27.1%)	293 (25.3%)	0.629
Nausea	197	29 (20.7%)	168 (14.5%)	0.052
Abdominal cramps	224	27 (19.3%)	197 (17.0%)	0.496
Diarrhoea	244	26 (18.6%)	218 (18.8%)	0.949
Constipation	200	20 (14.3%)	180 (15.5%)	0.703
Vomiting	34	6 (4.3%)	28 (2.4%)	0.190
Faecal incontinence	17	4 (2.9%)	13 (1.1%)	0.088
Other (gastrointestinal)	8	0 (0.0%)	8 (0.7%)	0.324
Cardiovascular				
Cold hands/feet	285	32 (22.9%)	253 (21.8%)	0.777
Palpitations	163	30 (21.4%)	133 (11.5%)	0.001
Low blood pressure	67	11 (7.9%)	56 (4.8%)	0.126
High blood pressure	60	7 (5.0%)	53 (4.6%)	0.818
Excessive bleeding from cuts/wounds	17	2 (1.4%)	15 (1.3%)	0.894
Other (cardiovascular)	6	2 (1.4%)	4 (0.3%)	0.074
Blood clots	2	0 (0.0%)	2 (0.2%)	0.623
Mental health				
Stress	742	76 (54.3%)	666 (57.4%)	0.48
Anxiety	619	72 (51.4%)	547 (47.2%)	0.339
Difficulty to sleep at night	566	69 (49.3%)	497 (42.8%)	0.147
Frustration	581	60 (42.9%)	521 (44.9%)	0.644
Sadness	543	59 (42.1%)	484 (41.7%)	0.924
Difficult to wake up in the morning	436	47 (33.6%)	389 (33.5%)	0.993
Mood swings	436	54 (38.6%)	382 (32.9%)	0.182
Depression	277	31 (22.1%)	246 (21.2%)	0.798
Loneliness	302	24 (17.1%)	278 (24.0%)	0.071
Nervous breakdown	39	4 (2.9%)	35 (3.0%)	0.916
Other (mental health)	13	3 (2.1%)	10 (0.9%)	0.150
Other				
Unusual fatigue/tiredness after exertion	258	55 (39.3%)	203 (17.5%)	<0.001
Muscle aches/pains	357	43 (30.7%)	314 (27.1%)	0.361
Neck/shoulder pain	467	41 (29.3%)	426 (36.7%)	0.083
Joint pains	328	40 (28.6%)	288 (24.8%)	0.335
Back pain	443	40 (28.6%)	403 (34.7%)	0.146
Disruption of the menstrual cycle	110	17 (12.1%)	93 (8.0%)	0.098
Sinus pain	129	14 (10.0%)	115 (9.9%)	0.974
Hair loss	99	13 (9.3%)	86 (7.4%)	0.430
Lymph nodes/glands (parotid/neck/ears, etc)	81	12 (8.6%)	69 (5.9%)	0.225

Urinary incontinence	41	8 (5.7%)	33 (2.8%)	0.066
Fever	27	4 (2.9%)	23 (2.0%)	0.493
Other (other)	9	2 (1.4%)	7 (0.6%)	0.266

Table 3 Multivariable logistic regression odds ratio (OR) and adjusted odds ratio (aOR) estimates of symptoms of interest

Symptom group / symptom	Total N (%) n=1,233	Cases N (%) n=140	Control group N (%) n=1,160	P-value	OR	95% CI	aOR*	95% CI	P-value
Sensory									
Loss of taste	31	24 (17.1%)	7 (0.6%)	<0.001	34.08	14.37-80.80	39.69	15.50-101.61	<0.001
Loss of smell	35	26 (18.6%)	9 (0.8%)	<0.001	29.17	13.34-63.76	33.88	14.45-79.45	<0.001
Loss of appetite	87	20 (14.3%)	67 (5.8%)	<0.001	2.72	1.59-4.64	3.15	1.74-5.68	<0.001
Blurred vision	99	19 (13.6%)	80 (6.9%)	0.005	2.12	1.24-3.62	2.61	1.47-4.66	0.001
Metallic taste in the mouth	64	14 (10.0%)	50 (4.3%)	0.003	2.47	1.33-4.59	2.18	1.12-4.26	0.022
Neurological									
Short-term memory loss	94	29 (20.7%)	65 (5.6%)	<0.001	4.40	2.73-7.11	5.66	3.31-9.67	<0.001
Confusion/brain fog/trouble focusing attention	209	39 (27.9%)	170 (14.7%)	<0.001	2.25	1.50-3.37	2.82	1.81-4.38	<0.001
Forgetfulness	269	49 (35.0%)	220 (19.0%)	<0.001	2.30	1.58-3.35	2.62	1.74-3.95	<0.001
Trembling	28	8 (5.7%)	20 (1.7%)	0.002	3.45	1.49-8.00	4.27	1.72-10.59	0.002
Trouble trying to form words	129	22 (15.7%)	107 (9.2%)	0.015	1.83	1.12-3.02	2.24	1.32-3.81	0.003
Difficulty swallowing	37	9 (6.4%)	28 (2.4%)	0.007	2.78	1.28-6.01	3.17	1.38-7.26	0.006
Problems with sleeping through the night	682	85 (60.7%)	597 (51.5%)	0.038	1.46	1.02-2.09	1.63	1.11-2.39	0.013
Coughing when lying down	80	14 (10.0%)	66 (5.7%)	0.045	1.84	1.01-3.37	2.27	1.18-4.37	0.014
Twitching of fingers and toes	36	8 (5.7%)	28 (2.4%)	0.025	2.45	1.09-5.49	2.43	1.01-5.80	0.046
Respiratory									
Breathlessness after minimal exertion	154	36 (25.7%)	118 (10.2%)	<0.001	3.06	2.00-4.67	3.52	2.20-5.62	<0.001
Breathlessness at rest	46	13 (9.3%)	33 (2.8%)	<0.001	3.50	1.79-6.81	3.51	1.68-7.32	0.001
Chest tightness/pain	121	26 (18.6%)	95 (8.2%)	<0.001	2.56	1.59-4.11	2.94	1.75-4.93	<0.001
Unusual fatigue/tiredness after exertion	258	55 (39.3%)	203 (17.5%)	<0.001	3.01	2.10-4.42	2.72	1.82-4.07	<0.001
Fits of coughing	94	19 (13.6%)	75 (6.5%)	0.002	2.27	1.33-3.89	2.12	1.19-3.75	0.010
Cardiovascular									
Palpitations	163	30 (21.4%)	133 (11.5%)	0.001	2.11	1.35-3.28	1.93	1.20-3.10	<0.001

*Adjusted for age group, sex, ethnicity, workplace setting and comorbidity status

~Missing observations: 23

Table 4 Adjusted odds ratios (aOR) estimates using multivariable logistic models of symptoms of interest grouped by cluster

Cluster	Total N (%) n=1,233	Cases N (%) n=140	Uninfected N (%) n=1,160	OR	95% CI	P-value	aOR	95% CI	P-value
Sensory <i>Loss of smell OR loss of taste OR blurred vision OR loss of appetite</i>	191	53 (37.9%)	138 (11.9%)	4.51	3.07-6.63	<0.001	5.25	3.45-8.01	<0.001
Neurological <i>Forgetfulness OR confusion OR short- term memory loss</i>	323	59 (42.1%)	264 (22.8%)	2.47	1.72-3.55	<0.001	2.77	1.87-4.11	<0.001
Cardiorespiratory <i>Unusual fatigue OR palpitations OR breathlessness after minimal exertion OR chest tightness/pain OR breathless at rest</i>	446	72 (51.4%)	374 (32.4%)	2.23	1.56-3.17	<0.001	2.06	1.42-3.01	<0.001

*Adjusted for age group, sex, ethnicity, workplace setting and comorbidity status

~Missing observations: 23

Figure 2 Venn diagrams representing the most common systems affected among cases compared to the control group

References

1. Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. *Postgraduate Medical Journal*. 2020:postgradmedj-2020-138577.
2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. *Clinical immunology (Orlando, Fla)*. 2020;215:108427.
3. Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Research*. 2020;6(4):00542-2020.
4. Mahase E. Covid-19: What do we know about "long covid"? *BMJ (Clinical research ed)*. 2020;370:m2815.
5. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A, et al. More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis. *Res Sq*. 2021.
6. NICE. COVID-19 rapid guideline: managing the long-term effects of COVID-19 2020 [Available from: <https://www.nice.org.uk/guidance/ng188>].
7. Nabavi N. Long covid: How to define it and how to manage it. *BMJ (Clinical research ed)*. 2020;370:m3489.
8. Kingstone T, Taylor AK, O'Donnell CA, Atherton H, Blane DN, Chew-Graham CA. Finding the 'right' GP: a qualitative study of the experiences of people with long-COVID. *BJGP open*. 2020.
9. Cirulli ET, Barrett KMS, Riffle S, Bolze A, Neveux I, Dabe S, et al. Long-term COVID-19 symptoms in a large unselected population. *medRxiv*. 2020:2020.10.07.20208702.
10. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *The Lancet*. 2021;397(10270):220-32.
11. Burke D. Full list of 170 long-Covid symptoms leaving patients with hair loss and crippling pain. *The Daily Mirror*. 2020.
12. Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological surveillance of SARS-CoV-2: trends and humoral response in a cohort of public health workers. *medRxiv*. 2020:2020.10.21.20216689.
13. Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers. *Journal of Infection*.
14. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. *medRxiv*. 2020:2020.10.19.20214494.
15. Carfi A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. *Jama*. 2020;324(6):603-5.
16. Lex A, Gehlenborg N, Strobel H, Vuilleumot R, Pfister H. UpSet: Visualization of Intersecting Sets. *IEEE Trans Vis Comput Graph*. 2014;20(12):1983-92.
17. Baig AM. Chronic COVID Syndrome: Need for an appropriate medical terminology for Long-COVID and COVID Long-Haulers. *Journal of medical virology*. 2020.
18. Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. *The European respiratory journal*. 2020;56(5).
19. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? *Lung*. 2021:1-7.
20. Halpin S, O'Connor R, Sivan M. Long COVID and chronic COVID syndromes. *Journal of medical virology*. 2021;93(3):1242-3.
21. The prevalence of long COVID symptoms and COVID-19 complications. In: ONS, editor. 2020.
22. van Riel D, Verdijk R, Kuiken T. The olfactory nerve: a shortcut for influenza and other viral diseases into the central nervous system. *The Journal of pathology*. 2015;235(2):277-87.
23. Özçelik Korkmaz M, Eğilmez OK, Özçelik MA, Güven M. Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection. *European archives of oto-rhino-laryngology*

- : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery. 2020;1-11.
24. Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. *Radiology*. 2020;296(2):E55-e64.
 25. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. *Clin Med (Lond)*. 2021;21(1):e63-e7.
 26. Kreye J, Reincke SM, Prüss H. Do cross-reactive antibodies cause neuropathology in COVID-19? *Nature Reviews Immunology*. 2020;20(11):645-6.
 27. Islam MF, Cotler J, Jason LA. Post-viral fatigue and COVID-19: lessons from past epidemics. *Fatigue: Biomedicine, Health & Behavior*. 2020;8(2):61-9.
 28. Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. *BMC neurology*. 2011;11:37.
 29. Torrente M, Sousa PAC, Sánchez-Ramos A, Pimentao J, Royuela A, Franco F, et al. To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic. *BMJ Open*. 2021;11(2):e044945.